ClinicalTrials.gg
CompletedNCT06991179Updated Sep 23, 2025

A Study of Food Effect and Esomeprazole on LY4064809 in Healthy Adult Participants

A Phase 1 interventional study of LY4064809 in Healthy, sponsored by Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-23.

Sponsored by Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and effect of food on LY4064809 and the safety and effect of stomach changes by a proton pump inhibitor (PPI) esomeprazole, under fasted conditions in healthy adult participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

First submitted after Scorpion Therapeutics became part of Eli Lilly and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are healthy as determined by no findings from medical history, physical examination, 12-lead (ECG), vital sign measurements, or clinical laboratory evaluations at screening and/or admission as assessed by the investigator (or designee)
  • Participants have normal blood pressure and pulse rate, as determined by the investigator
  • Have venous access sufficient to allow for blood sampling
  • Have a (BMI) within the range 18-32 kilogram/square meter (kg/m²) (inclusive)
  • Individuals not of and individuals assigned male at birth may participate in this trial

Exclusion criteria

Exclusion Criteria:

  • History or presence of any of the following conditions, deemed by the investigator (or designee), which may significantly alter the absorption, metabolism, or elimination of drugs, constitute a risk when taking the study intervention or interfere with the data interpretation:

    • Metabolic disease, including congenital non-hemolytic hyperbilirubinemia (for example, Gilbert syndrome),
    • Biliary disease, including cholecystectomy,
    • Gastrointestinal (GI) disease,
    • Hematological disease,
    • Neurological disease,
    • Significant history of, or presence of hepatic disease, including any abnormal liver function tests and serum total above the 1.5

      × (ULN) range per the laboratory's reference ranges at screening or admission, or

    • Clinically significant, active cardiovascular disease or history of myocardial infarction within 6 months prior to the planned start of LY4064809
  • History of a major surgical procedure within 30 days prior to screening
  • Diagnosed and/or treated within 5 years prior to screening with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and curatively resected in situ carcinoma of the cervix.
  • Have known allergies to LY4064809 or related compounds or esomeprazole or related compounds
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Group 1 Treatment A Fasted

    LY4064809 administered orally

    Drug: LY4064809

  • Experimental
    Group 1 Treatment B High-Fat Meal

    LY4064809 administered orally

    Drug: LY4064809

  • Experimental
    Group 2 Treatment A Fasted

    LY4064809 administered orally

    Drug: LY4064809

  • Experimental
    Group 2 Treatment C Proton Pump Inhibitor (PPI) Effect

    LY4064809 administered orally with esomeprazole

    Drug: LY4064809

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4064809

    PK: Cmax of LY4064809

    Time frame: Day 1 to Approximately Day 47

  2. Pharmacokinetics (PK): Area Under the Concentration versus Time Curve from Time Zero to Time T (AUC 0-tlast)

    PK: AUC 0-tlast, where t is the last time point with a measurable concentration

    Time frame: Day 1 to Approximately Day 47

  3. Pharmacokinetics (PK): Area Under the Concentration versus Time Curve from Zero to Infinity (AUCinf)

    PK: AUCinf

    Time frame: Day 1 to Approximately Day 47

07

Study locations

1 site
  • Pharmaron Clinical Pharmacology Center Inc
    Baltimore, Maryland 21201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Sep 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2025
First posted
May 26, 2025
StartActual
May 20, 2025
Primary completionActual
Sep 2, 2025
CompletionActual
Sep 2, 2025
Last update
Sep 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06991179
Responsible party
Sponsor
First posted
May 26, 2025
Start date
May 20, 2025
Primary completion
Sep 2, 2025
Completion
Sep 2, 2025
Last update
Sep 23, 2025

Study contacts

1-877-CTLilly (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: STX-478

Start the discussion